PDX Pharmaceuticals Inc.
Portland, OR
- UEI
- VTX7JRKLC3F5
- CAGE
- 66ST6
- Primary NAICS
- 541713 Research and Development in Nanotechnology
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 3303 S Bond Ave, Portland, OR 97239, USA
- Website
- pdxpharm.com
- Founded
- 2010
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Advancing the commercialization readiness of nanoparticle-based immunotherapy for cancer treatment - treatment of… | National Cancer Institute | $410,652 | |
| PLK1 and egfr targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer - lung cancer is the… | National Cancer Institute | $7,345,247 | |
| Novel nano-immunotherapy for treatment of non-small cell lung cancer - treatment of non-small cell lung cancer (nsclc)… | National Cancer Institute | $5,797,845 | |
| In situ tumor vaccination with a nano-oligo therapeutic to induce whole-body antitumor immune response -… | National Cancer Institute | $5,898,361 | |
| Development of topical formulation of sirna-nanoparticle for treating skin diseases | National Center for Advancing Translational Sciences | $325,000 |
About PDX Pharmaceuticals Inc.
PDX Pharmaceuticals Inc. is a biotechnology company registered in SAM.gov since 2010, specializing in developing innovative nanoparticle-based immunotherapies for cancer treatment. The company is a minority-owned, woman-owned business focused on advanced pharmaceutical research and development, with a particular emphasis on creating novel therapeutic approaches for challenging cancer types. Their core expertise lies in nanotechnology and cancer systems biology, enabling them to design sophisticated drug delivery platforms that maximize treatment efficacy while minimizing toxicity.
The company has secured multiple federal grants from the National Cancer Institute, specifically focused on developing advanced immunotherapies for non-small cell lung cancer (NSCLC). Their primary research initiatives include developing nanoconstructs like ARAC-02 and PETTRA, which utilize sophisticated nanoparticle platforms to co-deliver multiple therapeutic agents such as siRNA, antibodies, and immune stimulants. These grants, ranging from $321,304 to unspecified amounts, support research aims like pursuing international patent protection, initiating GMP-compliant manufacturing, optimizing nanoparticle constructs, and conducting preclinical efficacy and safety evaluations. PDX Pharmaceuticals has partnered with research institutions like Oregon Health and Science University, and leverages advanced techniques like in situ tumor vaccination and targeted drug delivery to potentially improve cancer treatment outcomes, particularly for patients resistant to current immunotherapy approaches.
Quick answers
What is PDX Pharmaceuticals Inc.'s UEI?
PDX Pharmaceuticals Inc.'s Unique Entity ID (UEI) in SAM.gov is VTX7JRKLC3F5.
What is PDX Pharmaceuticals Inc.'s CAGE code?
PDX Pharmaceuticals Inc.'s CAGE code is 66ST6.
What is PDX Pharmaceuticals Inc.'s primary NAICS code?
PDX Pharmaceuticals Inc.'s primary NAICS code is 541713 (Research and Development in Nanotechnology).
Where is PDX Pharmaceuticals Inc. located?
PDX Pharmaceuticals Inc.'s physical address in SAM.gov is 3303 S Bond Ave, Portland, OR 97239, USA.
Is PDX Pharmaceuticals Inc. registered in SAM.gov?
Yes. PDX Pharmaceuticals Inc.'s SAM.gov registration is active through September 15, 2027.
What is PDX Pharmaceuticals Inc.'s most recent federal award?
PDX Pharmaceuticals Inc.'s most recent federal grant award is Advancing the commercialization readiness of nanoparticle-based immunotherapy for cancer treatment - treatment of… (SB1CA287735), from National Cancer Institute, on September 5, 2024.
On GovTribe
See PDX Pharmaceuticals Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors